Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumor aggressiveness and target of KAT inhibitor CPTH2

Fig. 1

HAT inhibitor CPTH2 decreases cell viability in tumor cells. a In vitro HAT activity was measured in nuclear extracts of Thyroid papillary K1 (gray) and clear cell renal carcinoma ccRCC 786-O (dark gray) cell lines treated with CPTH2 (100 μM) for 24 and 48 h, respectively, and compared to untreated and DMSO samples. b Cell proliferation measured in K1 (gray) and 786-O (dark gray) cell lines in DMSO or during CPTH2 treatment at increased times (h) showed strong reduction at 48 h. c FACS analysis of 786-O cell line grown in DMSO and treated for 48 h with CPTH2. d Apoptotic FACS profile and percentage of apoptotic cells strongly enhanced after 48 h CPTH2 treatment in both K1 and 786-O cell lines

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us